Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era

Journal of Infectious Diseases

Volumn 180, Issue 6, 1999, Pages 1809-1818

  Martin, Jeffrey N ^a,b,c   Rose, David A ^c   Hadley, W Keith ^c   Perdreau Remington, Francoise ^c   Lam, Phung K ^a,b   Gerberding, Julie L ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CHILD; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MICROBIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, PNEUMOCYSTIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0032758636     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315132     Document Type: Article

References (31)

1. 1. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992; 327: 1842-8.
2. 2. Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 1992; 327:1836-41.
3. 3. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996; 156:177-88.
4. 4. Cockerill FR, Edson RS. Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1991;66:1260-9.
5. 5. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. MMWR Morb Mortal Wkly Rep 1997;46(RR-12):1-46.
6. 6. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 -infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999; 340: 1301-6.
7. 7. Wilson JM, Guiney DG. Failure of oral trimethoprim-sulfamethoxazole prophylaxis in acute leukemia: isolation of resistant plasmids from strains of Enterobacteriaceae causing bacteremia. N Engl J Med 1982; 306:16-20.
8. 8. Dekker AW, Rozenberg-Arska M, Sixma JJ, Verhoef J. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann Intern Med 1981;95:555-9.
9. 9. Slobod KS, Leggiadro RJ. Trimethoprim-sulfamethoxazole-resistant pneumococcal disease in a pediatric acquired immunodeficiency syndrome patient receiving trimethoprim-sulfamethoxazole prophylaxis. Pediatr Infect Dis J 1994; 13:423-4.
10. 10. de la Rubia F, Clavo A, Lopez Prieto D, et al. Antimicrobial susceptibility of Streptococcus pneumoniae in HIV patients. In: Report: Tenth International AIDS/International Conference on STD. The global challenge of AIDS: together for the future. (Yokahama, Japan, 7-12 August 1994). Tokyo: Japanese Foundation for AIDS Prevention, 1995.
11. 11. Meynard JL, Barbut F, Blum L, et al. Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 22:437-40.
12. 12. Kadree M. High prevalence of trimethoprim-sulfamethoxazole(TMP-SMX) resistant Streptococcus pneumoniae in HIV-infected patients on TMP-SMX for pneumocystis prophylaxis: therapeutic implications. In: Program and abstracts: XI International Conference on AIDS (Vancouver, Canada. 7-12 July 1996). Vancouver: XI International Conference on AIDS Society, 1996.
13. 13. Rodriguez-Barradas MC, Tharapel RA, Groover JE, et al. Colonization by Streptococcus pneumoniae among human immunodeficiency virus infected adults: prevalence of antibiotic resistance, impact of immunization, and characterization by polymerase chain reaction with BOX primers of isolates from persistent S. pneumoniae carriers. J Infect Dis 1997; 175:590-7.
14. 14. Centers for Disease Control. Surveillance for penicillin-nonsusceptible Streptococcus pneumoniae - New York City, 1995. MMWR Morb Mortal Wkly Rep 1997;46:297-9.
15. 15. Landi B, Eliaszewicz M, Mainardi JL, Goldstein FW, Dupont B. Penicillin-resistant Streptococcus pneumoniae broncho-pulmonary infections in HIV-infected patients: risk factors for penicillin resistance. In: 5th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Alexandria, VA, 1-5 February 1998). Alexandria, VA: Infectious Diseases Society of America, 1998.
16. 16. National Committee on Clinical Laboratory Standards. Vol. 14, no. 16. Document M7-A3, Table 2. Wayne, PA: National Committee on Clinical Laboratory Standards, 1994.
17. 17. The Pulmonary Complications of HIV Infection Study Group. Design of a prospective study of the pulmonary complications of human immunodeficiency virus infection. J Clin Epidemiol 1993;46:497-507.
18. 18. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1989; 38(S 5):1-9.
19. 19. Centers for Disease Control. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1992;4I(RR-4):1-11.
20. 20. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons, 1981:13-5.
21. 21. Selvin S. Statistical analysis of epidemiologic data. New York: Oxford University Press, 1991.
22. 22. Stata Corporation. Version 5.0. College Station, Texas. 1997.
23. 23. San Francisco Department of Public Health AIDS Office. AIDS surveillance report. San Francisco: San Francisco Dept. of Public Health AIDS Office, 1 March 1997.
24. 24. Gurwith MJ, Brunton JL, Lank BA, Harding GK, Ronald AR. A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 1979;66:248-56.
25. 25. Weiser B, Lange M, Fialk MA, Singer C, Sztrowski TH, Armstrong D. Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: a controlled trial. Ann Intern Med 1981;95: 436-8.
26. 26. Gualtieri RJ, Donowitz GR, Kaiser DL, Hess CE, Sande MA. Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med 1983; 74:934-40.
27. 27. Goorin AM, Hershey BJ, Levin MJ, et al. Use of trimethoprim-sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatr Infect Dis 1985;4:265-9.
28. 28. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 1987; 106:7-11.
29. 29. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995; 333:845-51.
30. 30. Sassan-Morroko M, Wiktor SZ, Abouya L, et al. Significant reduction in mortality attributable to cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Ivory Coast. In: Program and abstracts: XII World AIDS Conference (Geneva, 1198). Stockholm: International AIDS Society, 1998.
31. 31. Anglaret X, Chene G, Attia A, Toure S, Nidri-Yoman T, Salamon R. Early cotrimoxazole (Cmx) chemoprophylaxis for HIV-infected adults in Africa: a double-blind placebo-controlled trial. In: Program and abstracts: XII World AIDS Conference (Geneva, 1998). Stockholm: International AIDS Society, 1998.